July 2010
 

XVIII International AIDS Conference Citations

POSTER Drug-resistant genotyping to guide selection of etravirine, darunavir and raltegravir in salvage therapy for multi-drug-resistant cases improves outcomes N. Miyazaki, S. Matsushita, T. Fujii, et al PDF Poster     Abstract POSTER Duration of antiretroviral regimens including Raltegravir, Maraviroc, Darunavir and/or Etravirine in clinical practice I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al PDF Poster    Abstract POSTER Efficacy, safety and tolerability of etravirine (ETR) as salvage therapy in HIV-1-infected paediatric patients in clinical practice V. Briz, C. Palladino, M.L. Navarro, et al PDF Poster    Abstract A phase IV, double blind, multi centre, randomised, placebo controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz (EFV) with continuing central nervous system ( CNS) adverse events (AE) to etravirine (ETR) L. Waters, M. Fisher, A. Winston, et al Genotypic resistance to darunavir, tipranavir and etravirine in patients with failure to two or more ARV combinations in Mexico E. Vidal-Laurencio, L. Cabrera-Ruiz, A. Flores-Gaxiola, et al "Switch-EE": randomized double-blind cross-over comparison of etravirine and efavirenz - final per-protocol analysis from the Swiss HIV cohort (SHCS) A. Nguyen, A. Calmy, B. Hirschel1, et al The SENSE trial: etravirine (ETR) shows fewer neuropsychiatric adverse events than efavirenz (EFV) i n treatment-naïve HIV-1 infected patients B. Gazzard, G. Di Perri, H. Furrer, et al

Journal Citations

• A WEEK-IN-REVIEW FEATURED REPORT
  A Review of the Safety and Tolerability Profile of the Next-Generation
  NNRTI Etravirine.
  Grinsztejn B, Di Perri G, Towner W, et al AIDS Res Hum Retroviruses. 2010 Jul 12.